Intercept Pharmaceuticals, Inc. focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. Intercept also has a license agreement with Aralez Pharmaceuticals Canada to develop and commercialize bezafibrate.
Market Cap | 447.12 Million | Shares Outstanding | 41.67 Million | Avg 30-day Volume | 1.881 Million |
P/E Ratio | 2.704 | Dividend Yield | 0.0 | EPS | 6.37 |
Price to Revenue | 1.9001 | Debt to Equity | 4.9571 | EBITDA | -64.874 Million |
Price to Book Value | 8.3297 | Operating Margin | -24.9285 | Enterprise Value | 457.453 Million |
Current Ratio | 2.368 | EPS Growth | 3.857 | Quick Ratio | 2.232 |
1 Yr BETA | 1.1625 | 52-week High/Low | 21.86 / 8.82 | Profit Margin | 70.2715 |
Operating Cash Flow Growth | -790.7187 | Altman Z-Score | -4.4157 | Free Cash Flow to Firm | -76.403 Million |
Earnings Report | 2023-08-03 |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
|
39,471 | 2023-05-24 | 1 | |
|
686,686 | 2023-05-24 | 1 | |
|
31,756 | 2023-05-24 | 1 | |
|
31,558 | 2023-05-24 | 1 | |
|
43,905 | 2023-05-24 | 1 | |
|
33,598 | 2023-05-24 | 1 | |
|
32,830 | 2023-05-24 | 1 | |
|
26,391 | 2023-05-24 | 1 | |
|
30,415 | 2023-05-24 | 1 | |
FREEDBERG JARED GENERAL COUNSEL |
|
57,985 | 2023-05-01 | 6 |
SAIK ANDREW EVP & CHIEF FINANCIAL OFFICER |
|
70,081 | 2023-03-21 | 6 |
BERREY M MICHELLE PRESIDENT, R&D & CMO |
|
82,631 | 2023-03-14 | 6 |
RICHARDSON LINDA M EVP & CHIEF COMMERCIAL OFFICER |
|
43,291 | 2023-02-14 | 5 |
DURSO JEROME BENEDICT PRESIDENT & CEO |
|
237,340 | 2023-01-27 | 2 |
FORD DAVID A CHIEF HUMAN RESOURCES OFFICER |
|
52,438 | 2023-01-27 | 2 |
VENEZIA ROCCO CHIEF ACCOUNTING OFFICER |
|
41,451 | 2023-01-27 | 3 |
BALL BRYAN CHIEF QUAL. OFFICER & SVP OPS. |
|
25,178 | 2022-07-11 | 1 |
CAWKWELL GAIL SVP, MED AFFAIRS, SAFETY & PV |
|
35,740 | 2022-02-12 | 0 |
DEFRANCESCO LISA SVP, IR & CORP. AFFAIRS |
|
10,308 | 2021-12-31 | 0 |
|
618,894 | 2021-11-30 | 0 | |
WEYER CHRISTIAN EVP, RESEARCH & DEVELOPMENT |
|
27,341 | 2021-04-01 | 0 |
KAPADIA SANDIP CFO AND TREASURER |
|
40,964 | 2021-01-22 | 0 |
CAMPAGNA JASON CHIEF MEDICAL OFFICER |
|
20,531 | 2021-01-22 | 0 |
KIM RICHARD J PRESIDENT US COMM & STRAT MKTG |
|
19,770 | 2020-12-31 | 0 |
SULLIVAN RYAN T GENERAL COUNSEL AND SECRETARY |
|
24,708 | 2020-11-13 | 0 |
|
4,000,000 | 2020-08-13 | 0 | |
|
4,000,000 | 2020-08-13 | 0 | |
BRIGHT LISA PRESIDENT, INTERNATIONAL |
|
22,012 | 2020-07-01 | 0 |
|
8,060 | 2020-05-28 | 0 | |
SHAPIRO DAVID CHIEF MEDICAL OFFICER |
|
39,499 | 2019-05-01 | 0 |
BRIGHT LISA PRESIDENT, INTERNATIONAL BRIGHT LISA PRESIDENT, INTERNATIONAL |
|
18,807 | 2019-01-07 | 0 |
MCMINN RACHEL CHIEF STRATEGY OFFICER |
|
16,875 | 2017-10-02 | 0 |
DUNCAN BARBARA GAYLE CHIEF ACCOUNTING OFFICER |
|
30,661 | 2016-10-03 | 0 |
ADORINI LUCIANO SEE REMARKS |
|
No longer subject to file | 2016-02-01 | 0 |
|
1,121,583 | 2015-11-24 | 0 | |
|
2,816 | 2015-11-24 | 0 | |
|
1,936 | 2015-11-20 | 0 | |
|
1,120,609 | 2015-07-17 | 0 | |
REGAN DANIEL PAUL CHIEF COMMERCIAL OFFICER |
|
1,264 | 2015-01-30 | 0 |
|
452 | 2014-07-17 | 0 | |
|
0 | 2014-07-07 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-05-25 20:39:30 -0400 | 2023-05-24 | A | 8,111 | a | 31,756 | direct | 4.9708 | 4.9708 | 2 | 0.0 | 1 | |||||
2023-05-25 20:40:49 -0400 | 2023-05-24 | A | 12,547 | a | 12,547 | direct | ||||||||||
2023-05-25 20:40:49 -0400 | 2023-05-24 | A | 8,111 | a | 33,598 | direct | 4.9708 | 4.9708 | 2 | 0.0 | 1 | |||||
2023-05-25 20:40:31 -0400 | 2023-05-24 | A | 12,547 | a | 12,547 | direct | ||||||||||
2023-05-25 20:40:31 -0400 | 2023-05-24 | A | 8,111 | a | 31,558 | direct | 4.9708 | 4.9708 | 2 | 0.0 | 1 | |||||
2023-05-25 20:39:52 -0400 | 2023-05-24 | A | 12,547 | a | 12,547 | direct | ||||||||||
2023-05-25 20:39:52 -0400 | 2023-05-24 | A | 8,111 | a | 43,905 | direct | 4.9708 | 4.9708 | 2 | 0.0 | 1 | |||||
2023-05-25 20:40:13 -0400 | 2023-05-24 | A | 12,547 | a | 12,547 | direct | ||||||||||
2023-05-25 20:40:13 -0400 | 2023-05-24 | A | 8,111 | a | 32,830 | direct | 4.9708 | 4.9708 | 2 | 0.0 | 1 | |||||
2023-05-25 20:39:30 -0400 | 2023-05-24 | A | 12,547 | a | 12,547 | direct | ||||||||||
2023-05-25 20:39:02 -0400 | 2023-05-24 | A | 12,547 | a | 12,547 | direct | ||||||||||
2023-05-25 20:39:02 -0400 | 2023-05-24 | A | 8,111 | a | 26,391 | direct | 4.9708 | 4.9708 | 2 | 0.0 | 1 | |||||
2023-05-25 20:38:05 -0400 | 2023-05-24 | A | 12,547 | a | 12,547 | direct | ||||||||||
2023-05-25 20:38:05 -0400 | 2023-05-24 | A | 8,111 | a | 30,415 | direct | 4.9708 | 4.9708 | 2 | 0.0 | 1 | |||||
2023-05-25 20:37:35 -0400 | 2023-05-24 | A | 12,547 | a | 12,547 | direct | ||||||||||
2023-05-25 20:37:35 -0400 | 2023-05-24 | A | 8,111 | a | 31,659 | direct | 4.9708 | 4.9708 | 2 | 0.0 | 1 | |||||
2023-05-25 20:37:15 -0400 | 2023-05-24 | A | 12,547 | a | 12,547 | direct | ||||||||||
2023-05-25 20:37:15 -0400 | 2023-05-24 | A | 8,111 | a | 45,998 | direct | 4.9708 | 4.9708 | 2 | 0.0 | 1 | |||||
2023-05-03 16:01:00 -0400 | 2023-05-01 | F | 771 | $17.07 | d | 57,985 | direct | 1.1264 | -2.2528 | 1.1264 | 2 | -2.2528 | 6 |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
INTERCEPT PHARMACEUTICALS IN ICPT | 2023-06-02 22:15:04 UTC | 4.6519 | 0.4081 | 800000 |
INTERCEPT PHARMACEUTICALS IN ICPT | 2023-06-02 21:45:04 UTC | 4.6519 | 0.4081 | 800000 |
INTERCEPT PHARMACEUTICALS IN ICPT | 2023-06-02 21:15:04 UTC | 4.6519 | 0.4081 | 800000 |
INTERCEPT PHARMACEUTICALS IN ICPT | 2023-06-02 20:45:03 UTC | 4.6519 | 0.4081 | 800000 |
INTERCEPT PHARMACEUTICALS IN ICPT | 2023-06-02 20:15:05 UTC | 4.6519 | 0.4081 | 800000 |
INTERCEPT PHARMACEUTICALS IN ICPT | 2023-06-02 19:45:04 UTC | 4.6519 | 0.4081 | 800000 |
INTERCEPT PHARMACEUTICALS IN ICPT | 2023-06-02 19:15:04 UTC | 4.6519 | 0.4081 | 800000 |
INTERCEPT PHARMACEUTICALS IN ICPT | 2023-06-02 18:45:04 UTC | 4.6519 | 0.4081 | 800000 |
INTERCEPT PHARMACEUTICALS IN ICPT | 2023-06-02 18:15:04 UTC | 4.6519 | 0.4081 | 800000 |
INTERCEPT PHARMACEUTICALS IN ICPT | 2023-06-02 17:45:03 UTC | 4.6519 | 0.4081 | 800000 |
INTERCEPT PHARMACEUTICALS IN ICPT | 2023-06-02 17:15:04 UTC | 4.6519 | 0.4081 | 800000 |
INTERCEPT PHARMACEUTICALS IN ICPT | 2023-06-02 16:45:03 UTC | 4.6608 | 0.4092 | 800000 |
INTERCEPT PHARMACEUTICALS IN ICPT | 2023-06-02 16:15:04 UTC | 4.6608 | 0.4092 | 800000 |
INTERCEPT PHARMACEUTICALS IN ICPT | 2023-06-02 15:45:04 UTC | 4.6608 | 0.4092 | 800000 |
INTERCEPT PHARMACEUTICALS IN ICPT | 2023-06-02 15:15:03 UTC | 4.6608 | 0.4092 | 800000 |
INTERCEPT PHARMACEUTICALS IN ICPT | 2023-06-02 14:45:04 UTC | 4.6608 | 0.4092 | 800000 |
INTERCEPT PHARMACEUTICALS IN ICPT | 2023-06-02 14:15:03 UTC | 4.6608 | 0.4092 | 800000 |
INTERCEPT PHARMACEUTICALS IN ICPT | 2023-06-02 13:45:03 UTC | 4.6608 | 0.4092 | 800000 |
INTERCEPT PHARMACEUTICALS IN ICPT | 2023-06-02 13:15:04 UTC | 4.6608 | 0.4092 | 800000 |
INTERCEPT PHARMACEUTICALS IN ICPT | 2023-06-02 12:45:03 UTC | 4.6608 | 0.4092 | 800000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
AQR Funds- AQR Multi-Strategy Alternative Fund | ICPT | -9.0 shares, $-373.14 | 2020-09-30 | N-PORT |
INVESTMENT MANAGERS SERIES TRUST- AAM HIMCO Global Enhanced Dividend Fund | ICPT | -1113.0 shares, $-25688.04 | 2021-03-31 | N-PORT |
Franklin Alternative Strategies Funds- K2 Alternative Strategies Fund | ICPT | -44947.0 shares, $-907030.46 | 2023-02-28 | N-PORT |